Evidence map›Paper›PMID 33912307›Full record

ArticleThe Pan African medical journal2021

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.

Marius Djoumbissie Tchoupe, Hanen Chaker, Mona Boudabbous, Salma Toumi, François Pegdebamba Kissou, Saba Gargouri, Khawla Kammoun, Faiçal Jarraya, Nabil Tahri, Soumaya Yaich and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Pan African medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Marius Djoumbissie TchoupeNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Hanen ChakerNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Mona BoudabbousHepato-Gastroenterology Department, Hedi Chaker University Hospital, Sfax, Tunisia.
Salma ToumiNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
François Pegdebamba KissouNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Saba GargouriMicrobiology Laboratory, Habib Bourguiba University Hospital, Sfax, Tunisia.
Khawla KammounNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Faiçal JarrayaNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Nabil TahriHepato-Gastroenterology Department, Hedi Chaker University Hospital, Sfax, Tunisia.
Soumaya YaichNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Mohamed Ben HmidaNephrology Department, Faculty of Medicine, Hedi Chaker University Hospital and UR 12ES14, Sfax, Tunisia.
Hopital Universitaire Hedi Chaker · TNHopital Universitaire Habib Bourguiba · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of chronic hepatitis C virus (HCV) infection in chronic hemodialysis patients remains an issue of great concern for nephrologists. In 2008 the kidney disease improving global outcomes working group suggested the use of pegylated interferon in end stage kidney disease patients treated by dialysis. Since then, series and some clinical trials on different direct-acting antiviral agents have shown better efficacy and tolerance than interferon-based regimens. Data on the efficacy, tolerance and the right dose of sofosbuvir in this population are still unclear. We report a case of chronic HCV genotype 1b infection in a 47-year-old patient on maintenance hemodialysis successfully treated by a combination of sofosbuvir and ledipasvir for 12 weeks. Evolution was marked by the complete regression of the hepatic cytolysis, a complete and sustained virologic response with HCV viral load undetectable for a 24 months follow-up period. No adverse reaction was found. The treatment of HCV genotype 1 or 4 infection in patients on maintenance hemodialysis is possible with sofosbuvir based regimens with a good efficacy/safety ratio in the absence of current recommended drugs for patients with eGFR<30ml/min/1.73m

Indexed as

Renal DialysisAntiviral AgentsBenzimidazolesFluorenesFollow-Up StudiesGenotypeGlomerular Filtration RateHepacivirusHepatitis C, ChronicHumansKidney Failure, ChronicMaleMiddle AgedSofosbuvirSustained Virologic ResponseAntiviral AgentsBenzimidazolesFluorenesledipasvir, sofosbuvir drug combinationSofosbuvircase reportHemodialysishepatitis Csofosbuvirtreatment

Identifiers

PMID33912307
PMCPMC8052608
OpenAlexW3126706785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.